PMID- 24259694
OWN - NLM
STAT- MEDLINE
DCOM- 20140708
LR  - 20191210
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 47
IP  - 10
DP  - 2013 Oct
TI  - Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes.
PG  - 1301-11
LID - 10.1177/1060028013503626 [doi]
AB  - OBJECTIVE: To evaluate the available clinical data on canagliflozin and provide 
      formulary considerations as to its place in the current treatment approach of 
      type 2 diabetes mellitus (T2DM). DATA SOURCES: A systematic review of the 
      literature in MEDLINE and Web of Science was performed through July 2013 using 
      the key words and medical subject headings canagliflozin, JNJ-28431754, TA-7284, 
      and sodium-glucose co-transporter 2 inhibitor. A manual search of references from 
      reports of clinical trials or review articles was performed to identify 
      additional relevant studies. STUDY SELECTION AND DATA EXTRACTION: Citations 
      eligible for inclusion were in vitro or in vivo evaluations of canagliflozin with 
      no restrictions on patient population or indication used. Data related to the 
      patient populations and outcomes of interest were extracted from each citation. 
      DATA SYNTHESIS: Five clinical trials (n = 2775 subjects) have been published 
      evaluating canagliflozin in patients with T2DM. A single study evaluated 
      canagliflozin monotherapy, while the others included various add-on therapies. 
      Four studies included placebo groups with 2 others using sitagliptin as an active 
      control. Compared with placebo (+0.14%), canagliflozin monotherapy at doses of 
      100 to 300 mg/d decreases hemoglobin A1c by -0.77% to -1.03% from baseline. 
      Reductions in fasting plasma glucose, body weight, and systolic blood pressure 
      were seen. Because of the increase in glucosuria with the drug, patients 
      (especially females) are at increased risk of genital mycotic infections. The 
      overall safety of canagliflozin (eg, cardiovascular, oncologic, pancreatic, bone) 
      is also yet to be fully elucidated. CONCLUSIONS: Canagliflozin is comparable to 
      second-line oral medications in terms of effectiveness but has limitations in 
      affordability and long-term safety data.
FAU - Nigro, Stefanie C
AU  - Nigro SC
AD  - Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA.
FAU - Riche, Daniel M
AU  - Riche DM
FAU - Pheng, Michelle
AU  - Pheng M
FAU - Baker, William L
AU  - Baker WL
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20131008
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Thiophenes)
RN  - 0SAC974Z85 (Canagliflozin)
SB  - IM
MH  - Animals
MH  - Canagliflozin
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Glucosides/*administration & dosage/adverse effects/pharmacokinetics
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage/adverse effects/pharmacokinetics
MH  - Sodium-Glucose Transporter 2
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - Thiophenes/*administration & dosage/adverse effects/pharmacokinetics
OTO - NOTNLM
OT  - SGLT2 inhibitor
OT  - canagliflozin
OT  - type 2 diabetes mellitus
EDAT- 2013/11/22 06:00
MHDA- 2014/07/09 06:00
CRDT- 2013/11/22 06:00
PHST- 2013/11/22 06:00 [entrez]
PHST- 2013/11/22 06:00 [pubmed]
PHST- 2014/07/09 06:00 [medline]
AID - 1060028013503626 [pii]
AID - 10.1177/1060028013503626 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2013 Oct;47(10):1301-11. doi: 10.1177/1060028013503626. Epub 
      2013 Oct 8.